ES2174129T3 - Antagonistas de la hormona de liberacion de la gonadotropina. - Google Patents

Antagonistas de la hormona de liberacion de la gonadotropina.

Info

Publication number
ES2174129T3
ES2174129T3 ES96944249T ES96944249T ES2174129T3 ES 2174129 T3 ES2174129 T3 ES 2174129T3 ES 96944249 T ES96944249 T ES 96944249T ES 96944249 T ES96944249 T ES 96944249T ES 2174129 T3 ES2174129 T3 ES 2174129T3
Authority
ES
Spain
Prior art keywords
gonadotropina
liberation
antagonists
hormone
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96944249T
Other languages
English (en)
Inventor
Mark Goulet
Wallace T Ashton
Lin Chu
Michael H Fisher
Narindar N Girotra
Peter Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603242.0A external-priority patent/GB9603242D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2174129T3 publication Critical patent/ES2174129T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I) Y A LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, QUE SON UTILES COMO ANTAGONISTAS DE GNRH Y QUE PUEDEN SER UTILES COMO TALES PARA EL TRATAMIENTO DE DIVERSAS ALTERACIONES RELACIONADAS CON LAS HORMONAS SEXUALES Y CON OTRAS ALTERACIONES, TANTO EN HOMBRES COMO EN MUJERES.
ES96944249T 1995-12-14 1996-12-10 Antagonistas de la hormona de liberacion de la gonadotropina. Expired - Lifetime ES2174129T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US863395P 1995-12-14 1995-12-14
GBGB9603242.0A GB9603242D0 (en) 1996-02-16 1996-02-16 Antagonists of gonadotropin releasing hormone

Publications (1)

Publication Number Publication Date
ES2174129T3 true ES2174129T3 (es) 2002-11-01

Family

ID=26308721

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96944249T Expired - Lifetime ES2174129T3 (es) 1995-12-14 1996-12-10 Antagonistas de la hormona de liberacion de la gonadotropina.

Country Status (19)

Country Link
EP (1) EP0873336B1 (es)
JP (2) JP3230818B2 (es)
KR (1) KR19990072101A (es)
CN (1) CN1208412A (es)
AT (1) ATE215081T1 (es)
AU (1) AU707641B2 (es)
CA (1) CA2240108A1 (es)
CZ (1) CZ183998A3 (es)
DE (1) DE69620241T2 (es)
EA (1) EA000992B1 (es)
EE (1) EE9800173A (es)
ES (1) ES2174129T3 (es)
HU (1) HUP9903671A3 (es)
IL (1) IL124459A0 (es)
NO (1) NO982729L (es)
NZ (1) NZ325569A (es)
PL (1) PL327146A1 (es)
SK (1) SK77298A3 (es)
WO (1) WO1997021704A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9501608A (es) 1994-04-01 1997-02-28 Lilly Co Eli 1h-indol-3-glioxilamidas inhibidoras de spla2.
US6200957B1 (en) 1995-12-14 2001-03-13 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EE9800181A (et) * 1995-12-14 1998-12-15 Merck & Co., Inc. Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
WO1997021435A1 (en) * 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0986557A4 (en) * 1997-06-05 2001-03-14 Merck & Co Inc GONADOTROPIN RELEASING HORMON ANTAGONISTS
WO1998055123A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1998055116A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6017944A (en) * 1997-10-28 2000-01-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1049472A4 (en) * 1997-10-28 2002-04-03 Merck & Co Inc GONADOTROPIN RELEASING HORMON ANTAGONISTS
WO1999021553A1 (en) * 1997-10-28 1999-05-06 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2318957A1 (en) * 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5972898A (en) * 1998-03-27 1999-10-26 Abbott Laboratories 3',3-N-bis-substituted macrolide LHRH antagonists
US5955440A (en) * 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
JP2002510629A (ja) * 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
DE19815060A1 (de) * 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6020521A (en) * 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) * 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6346534B1 (en) 1998-09-23 2002-02-12 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US5981521A (en) * 1998-11-13 1999-11-09 Abbott Laboratories Tetrahydroisoquinoline derivatives as LHRH antagonists
US6537998B1 (en) 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
EP1255738B1 (en) 2000-01-25 2012-03-07 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
GB0022670D0 (en) 2000-09-15 2000-11-01 Astrazeneca Ab Molecules
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0101692D0 (sv) 2001-05-14 2001-05-14 Astrazeneca Ab Compounds
EP1411941A2 (en) 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
EP1412363A1 (en) 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
KR20040030893A (ko) 2001-08-02 2004-04-09 뉴로크린 바이오사이언시즈 인코퍼레이티드 치환된 피리딘-4-온 및 고나도트로핀 분비 호르몬 수용체길항제로서의 이의 용도
KR20040023712A (ko) 2001-08-02 2004-03-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 고나도트로핀 분비 호르몬 수용체(ｇｎｒｈ) 길항제로서의1,2,4-트리아진-3,5-디온
WO2003068769A1 (en) 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
EP1560818A1 (en) 2002-06-13 2005-08-10 Pfizer Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
KR100392768B1 (ko) 2002-08-09 2003-07-28 에스케이 텔레콤주식회사 발신 교환기를 이용한 가입자 기반 링백톤 서비스 방법
KR100378891B1 (ko) 2002-08-09 2003-04-08 에스케이 텔레콤주식회사 플렉시블 페이징시의 가입자 기반 링백톤 서비스 방법
US7253290B2 (en) 2002-08-21 2007-08-07 Astrazeneca Ab Pyrazole derivatives as GnRH inhibitors
TW200413351A (en) 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
ES2298545T3 (es) 2002-08-21 2008-05-16 Astrazeneca Ab Compuestos de tieno-pirrol como antagonistas de la hormona liberadora de gonadotropina.
GB0219472D0 (en) 2002-08-21 2002-10-02 Astrazeneca Ab Chemical compounds
TW200407127A (en) 2002-08-21 2004-05-16 Astrazeneca Ab Chemical compounds
WO2004023833A1 (en) * 2002-09-05 2004-03-18 Sk Telecom Co., Ltd. Method of managing trunk and querying and ascertaining ring-back sound to provide ring-back sound in subscriber-based ring-back sound service
US7045527B2 (en) 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
KR100393552B1 (ko) * 2002-10-01 2003-08-02 에스케이 텔레콤주식회사 교환기 음원 송출을 통한 가입자 기반 링백톤 서비스 방법
US7242757B2 (en) 2002-10-01 2007-07-10 Sk Telecom Co., Ltd. Method for providing a subscriber-based ringback tone sound
KR100393553B1 (ko) 2002-10-18 2003-08-02 에스케이 텔레콤주식회사 착신 미가입자에 대한 발신시 가입자 기반 링백톤 서비스방법
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2005007165A1 (en) 2003-07-07 2005-01-27 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
CN100376246C (zh) 2003-07-07 2008-03-26 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物
EP1644342B1 (en) 2003-07-07 2012-05-09 Neurocrine Biosciences, Inc. Arylpyrimidines useful for the treatment of sex hormone-related conditions such as endometriosis, prostate cancer and the like
WO2005108360A1 (en) 2004-05-07 2005-11-17 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
JP5137574B2 (ja) 2004-08-30 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドヒドロゲナーゼ阻害剤としての三環式ラクタム誘導体
JP5208505B2 (ja) 2004-08-30 2013-06-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのｎ−２アダマンタニル−２−フェノキシ−アセトアミド誘導体
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
KR101050568B1 (ko) 2006-12-07 2011-07-19 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항제로서의 스피로-피페리딘 유도체
WO2008077810A2 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
CN101663302B (zh) 2007-04-18 2013-07-24 橘生药品工业株式会社 含氮稠环衍生物、包含所述含氮稠环衍生物的药物组合物及其医药用途
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
TW201130854A (en) 2009-12-22 2011-09-16 Bayer Schering Pharma Ag Pyridinone derivatives and pharmaceutical compositions thereof
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
WO2012175514A1 (en) 2011-06-21 2012-12-27 Bayer Intellectual Property Gmbh Pyridinone derivatives and pharmaceutical compositions thereof
CN102260208A (zh) * 2011-07-28 2011-11-30 海门慧聚药业有限公司 4-吡啶丁醇的制备新工艺
EP2736330A4 (en) * 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
WO2019113693A1 (en) * 2017-12-12 2019-06-20 Queen's University At Kingston Compounds and methods for inhibiting cyp26 enzymes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4544663A (en) * 1984-05-07 1985-10-01 Sandoz, Inc. Indolamine derivatives as anti-fertility agents
US5030640A (en) * 1989-01-05 1991-07-09 Merck & Co., Inc. Novel β-adrenergic agonists and pharmaceutical compositions thereof
TW449600B (en) * 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use

Also Published As

Publication number Publication date
DE69620241T2 (de) 2002-10-02
PL327146A1 (en) 1998-11-23
JP2001106685A (ja) 2001-04-17
NO982729L (no) 1998-08-13
EE9800173A (et) 1998-12-15
HUP9903671A2 (hu) 2001-10-28
JPH11506471A (ja) 1999-06-08
IL124459A0 (en) 1998-12-06
MX9804765A (es) 1998-10-31
HUP9903671A3 (en) 2001-11-28
JP3230818B2 (ja) 2001-11-19
WO1997021704A1 (en) 1997-06-19
NO982729D0 (no) 1998-06-12
EP0873336B1 (en) 2002-03-27
CN1208412A (zh) 1999-02-17
EP0873336A1 (en) 1998-10-28
SK77298A3 (en) 1999-01-11
ATE215081T1 (de) 2002-04-15
KR19990072101A (ko) 1999-09-27
AU1410697A (en) 1997-07-03
AU707641B2 (en) 1999-07-15
EA000992B1 (ru) 2000-08-28
CA2240108A1 (en) 1997-06-19
CZ183998A3 (cs) 1998-10-14
NZ325569A (en) 2000-05-26
DE69620241D1 (de) 2002-05-02
EA199800563A1 (ru) 1998-12-24

Similar Documents

Publication Publication Date Title
ES2174129T3 (es) Antagonistas de la hormona de liberacion de la gonadotropina.
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
UY26782A1 (es) Derivados del benzotiazol
MX9300842A (es) Antagonistas de endotelina de sulfonamida.
ES2161290T3 (es) Derivados de quinazolina.
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
UY26968A1 (es) Agentes terapéuticos
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
CY1105931T1 (el) Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας
ES2110761T3 (es) Pirrolidin-3-il-alquil-piperidinas sustituidas utiles como antagonistas de la taquiquinina.
EA199800564A1 (ru) Антагонисты гонадотропин-высвобождающего фактора
PA8569201A1 (es) "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors"
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
BG66085B1 (bg) Фенилаланинови производни
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
ES2190486T3 (es) 3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina.
HN2001000280A (es) Derivados de piperidina como antagonstas selectivos de subtipo de n - metil - d - aspartato.
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas
CY1105370T1 (el) Μεθοδος θepαπειας των κλιμακτηριακων διαταραχων στις εμμηνοπαυσιακες και μετεμμηνοπαυσιακες γυναικες
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BR9809848A (pt) Composição

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 873336

Country of ref document: ES